Table 3 Overview of data source measurements and of the number of evaluations or assessments applied (n = 53)
From: Inventory of real world data sources in Parkinson’s disease
Nb | Study | Motor and neurological | Cognition | Psychiatry | Activities of daily living | Sleep | Quality of life | Autonomic | Other |
|---|---|---|---|---|---|---|---|---|---|
1 | A Longitudinal Observational Follow-up of the PRECEPT Study Cohort | 3 | 4 | 3 | 1 | 0 | 0 | 0 | 0 |
2 | Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3 | Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia | 2 | 14 | 1 | 0 | 0 | 0 | 0 | 0 |
4 | Arizona Study of Aging and Neurodegenerative Disease | 4 | 12 | 3 | 0 | 1 | 0 | 1 | 1 |
5 | Ashkenazi Jewish LRRK2 consortium cohort | 3 | 2 | 2 | 2 | 1 | 0 | 1 | 1 |
6 | Baltimore Longitudinal Study of Aging | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
7 | Boston university medical center - University of Alabama Birmingham - Washington University in Saint Louis School of medicine | 9 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
8 | Central Control of Mobility in Aging | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
9 | Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
10 | Charting the progression of disability in parkinson disease | 9 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
11 | Clinical course in Parkinson’s disease with elevated homocysteine | 1 | 9 | 1 | 1 | 0 | 0 | 0 | 0 |
12 | Clinical Research in Neurology (CRIN) - Emory center | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
13 | Comparative utility of the BESTest; mini-BESTest; and brief-BESTest for predicting falls in individuals with Parkinson disease: a cohort study | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
14 | Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson’s Disease | 3 | 1 | 2 | 2 | 1 | 3 | 0 | 0 |
15 | Contursi kindred | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
16 | Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
17 | Depression in Parkinson’s disease | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
18 | Dopamine agonist withdrawal syndrome in parkinson disease | 2 | 1 | 4 | 1 | 0 | 1 | 0 | 0 |
19 | Einstein Aging Study (Bronx Aging Study) | 2 | 11 | 1 | 0 | 0 | 0 | 0 | 0 |
20 | Emergence and evolution of social self-management of Parkinson’s disease | 2 | 2 | 1 | 1 | 0 | 4 | 0 | 0 |
21 | Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
22 | Harvard Alumni Health Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
23 | Health Professionals Follow-up Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
24 | Honolulu Asia Aging Study | 2 | 4 | 2 | 0 | 1 | 0 | 1 | 1 |
25 | Longitudinal study of normal cognition in Parkinson disease | 2 | 6 | 2 | 1 | 0 | 0 | 0 | 0 |
26 | Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson’s disease | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
27 | Loss of ability to work and ability to live independently in Parkinson’s disease | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
28 | Major life events and development of major depression in Parkinson’s disease patients | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
29 | Mayo Clinic cohort study of Personality and Aging (including Rochester Epidemiology project) | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
30 | Mayo clinic study of aging (Olmsted county resident) - Rochester Epidemiology project indexing system | 1 | 10 | 3 | 0 | 1 | 0 | 1 | 1 |
31 | Molecular Epidemiology of Parkinson’s Disease | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
32 | Mood and motor trajectories in Parkinson’s disease: multivariate latent growth curve modeling | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
33 | Mood and Subthalamic Nucleus Deep Brain Stimulation | 2 | 0 | 7 | 0 | 0 | 0 | 0 | 0 |
34 | Morris K Udall Parkinson’s Disease Research Center of Excellence cohort - Veteran affair | 2 | 3 | 2 | 1 | 0 | 1 | 0 | 1 |
35 | National Parkinson Foundation Quality Improvement Initiative | 3 | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
36 | NeuroGenetics Research Consortium | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
37 | Nurses’ Health Study | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
38 | Oxford Parkinson’s Disease Centre | 6 | 3 | 2 | 1 | 2 | 1 | 0 | 2 |
39 | Parkinson’s Associated Risk Study | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 |
40 | Parkinson’s Disease Biomarkers Program | 4 | 3 | 6 | 1 | 6 | 5 | 1 | 3 |
41 | Parkinson’s Disease Research Education and Clinical Center - Parkinson’s Genetic Research Study | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
42 | Parkinson’s disease: increased motor network activity in the absence of movement | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
43 | Parkinson’s progression biomarkers initiative | 1 | 5 | 4 | 2 | 2 | 0 | 1 | 2 |
44 | Prospective cohort study of impulse control disorders in Parkinson’s disease | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
45 | Rate of 6-18Ffluorodopa uptake decline in striatal subregions in Parkinson’s disease | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
46 | Religious Order Study | 6 | 11 | 4 | 1 | 0 | 0 | 0 | 0 |
47 | Rush Memory and Aging Project | 5 | 1 | 3 | 1 | 1 | 0 | 0 | 2 |
48 | Study of Osteoporotic Fractures (SOF) Research Group | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
49 | The effect of age of onset of PD on risk of dementia | 1 | 6 | 1 | 0 | 0 | 0 | 0 | 0 |
50 | University of California Los Angeles Center for Genes and Environmental in Parkinson’s Disease | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
51 | University of Miami Brain Endowment Bank | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
52 | UPDRS activity of daily living score as a marker of Parkinson’s disease progression | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
53 | Washington Heights-Inwood Columbia Aging | 1 | 6 | 0 | 1 | 0 | 0 | 0 | 0 |